{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,8,5]],"date-time":"2025-08-05T12:25:33Z","timestamp":1754396733607,"version":"3.41.2"},"reference-count":55,"publisher":"Wiley","issue":"4","license":[{"start":{"date-parts":[[2022,2,2]],"date-time":"2022-02-02T00:00:00Z","timestamp":1643760000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Pediatric Blood &amp; Cancer"],"published-print":{"date-parts":[[2022,4]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Although children and young adults with Hodgkin's lymphoma usually have a favorable prognosis, patients with primary refractory disease and some subsets of relapsed patients still have a dismal outcome. Brentuximab vedotin (BV) in combination with bendamustine may represent a suitable salvage therapy; data on 32 patients aged less than 25\u00a0years were retrospectively analyzed. Patients received up to six cycles of treatment of BV 1.8\u00a0mg\/kg on day 1 and bendamustine 90\u2013120\u00a0mg\/m<jats:sup>2<\/jats:sup> on days 2 and 3. At the end of treatment, the overall response rate was 81%. The 3\u2010year overall and progression\u2010free survivals are 78.1% and 67%, respectively.<\/jats:p>","DOI":"10.1002\/pbc.29557","type":"journal-article","created":{"date-parts":[[2022,2,2]],"date-time":"2022-02-02T13:30:36Z","timestamp":1643808636000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Brentuximab vedotin in combination with bendamustine in pediatric patients or young adults with relapsed or refractory Hodgkin lymphoma"],"prefix":"10.1002","volume":"69","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2803-992X","authenticated-orcid":false,"given":"Luciana","family":"Vinti","sequence":"first","affiliation":[{"name":"Department of Paediatric Haematology\/Oncology Cell and Gene Therapy Bambino Ges\u00f9 Children's Hospital IRCCS  Rome Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daria","family":"Pagliara","sequence":"additional","affiliation":[{"name":"Department of Paediatric Haematology\/Oncology Cell and Gene Therapy Bambino Ges\u00f9 Children's Hospital IRCCS  Rome Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Salvatore","family":"Buffardi","sequence":"additional","affiliation":[{"name":"Department of Paediatric Haematology\/Oncology Santobono Pausilipon Children's Hospital  Naples Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Valentina","family":"Di Ruscio","sequence":"additional","affiliation":[{"name":"Department of Paediatric Haematology\/Oncology Cell and Gene Therapy Bambino Ges\u00f9 Children's Hospital IRCCS  Rome Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francesca","family":"Stocchi","sequence":"additional","affiliation":[{"name":"Department of Paediatric Haematology\/Oncology Cell and Gene Therapy Bambino Ges\u00f9 Children's Hospital IRCCS  Rome Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elena","family":"Mariggi\u00f2","sequence":"additional","affiliation":[{"name":"Department of Paediatric Haematology\/Oncology Cell and Gene Therapy Bambino Ges\u00f9 Children's Hospital IRCCS  Rome Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rosanna","family":"Parasole","sequence":"additional","affiliation":[{"name":"Department of Paediatric Haematology\/Oncology Santobono Pausilipon Children's Hospital  Naples Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Antonia","family":"De Matteo","sequence":"additional","affiliation":[{"name":"Department of Paediatric Haematology\/Oncology Santobono Pausilipon Children's Hospital  Naples Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fara","family":"Petruzziello","sequence":"additional","affiliation":[{"name":"Department of Paediatric Haematology\/Oncology Santobono Pausilipon Children's Hospital  Naples Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Valeria","family":"Paganelli","sequence":"additional","affiliation":[{"name":"Department of Paediatric Haematology\/Oncology Cell and Gene Therapy Bambino Ges\u00f9 Children's Hospital IRCCS  Rome Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rita","family":"De Vito","sequence":"additional","affiliation":[{"name":"Department of Pathology Bambino Ges\u00f9 Children's Hospital, IRCCS  Rome Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francesca","family":"Del Bufalo","sequence":"additional","affiliation":[{"name":"Department of Paediatric Haematology\/Oncology Cell and Gene Therapy Bambino Ges\u00f9 Children's Hospital IRCCS  Rome Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Luisa","family":"Strocchio","sequence":"additional","affiliation":[{"name":"Department of Paediatric Haematology\/Oncology Cell and Gene Therapy Bambino Ges\u00f9 Children's Hospital IRCCS  Rome Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7976-3654","authenticated-orcid":false,"given":"Franco","family":"Locatelli","sequence":"additional","affiliation":[{"name":"Department of Paediatric Haematology\/Oncology Cell and Gene Therapy Bambino Ges\u00f9 Children's Hospital IRCCS  Rome Italy"},{"name":"Department of Pediatrics, Sapienza University of Rome  Rome Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2022,2,2]]},"reference":[{"doi-asserted-by":"publisher","key":"e_1_2_10_2_1","DOI":"10.1038\/sj.bjc.6604460"},{"doi-asserted-by":"publisher","key":"e_1_2_10_3_1","DOI":"10.1001\/jamanetworkopen.2020.27738"},{"issue":"1","key":"e_1_2_10_4_1","first-page":"1","article-title":"Italian cancer figures, report 2012: cancer in children and adolescents","volume":"37","author":"AIRTUM Working Group, CCM, AIEOP Working Group","year":"2013","journal-title":"Epidemiol Prev"},{"doi-asserted-by":"publisher","key":"e_1_2_10_5_1","DOI":"10.1200\/JCO.2014.59.4853"},{"doi-asserted-by":"publisher","key":"e_1_2_10_6_1","DOI":"10.3390\/cancers12061620"},{"doi-asserted-by":"publisher","key":"e_1_2_10_7_1","DOI":"10.6004\/jnccn.2011.0088"},{"doi-asserted-by":"publisher","key":"e_1_2_10_8_1","DOI":"10.1080\/10245332.2015.1115192"},{"doi-asserted-by":"publisher","key":"e_1_2_10_9_1","DOI":"10.1016\/j.ijrobp.2015.01.013"},{"doi-asserted-by":"publisher","key":"e_1_2_10_10_1","DOI":"10.1182\/asheducation\u20102016.1.323"},{"doi-asserted-by":"publisher","key":"e_1_2_10_11_1","DOI":"10.1111\/j.1365\u20102141.2011.08975.x"},{"doi-asserted-by":"publisher","key":"e_1_2_10_12_1","DOI":"10.3109\/10428194.2016.1140161"},{"doi-asserted-by":"publisher","key":"e_1_2_10_13_1","DOI":"10.1016\/S1470\u20102045(18)30426\u20101"},{"doi-asserted-by":"publisher","key":"e_1_2_10_14_1","DOI":"10.1002\/pbc.28167"},{"doi-asserted-by":"publisher","key":"e_1_2_10_15_1","DOI":"10.1200\/JCO.2008.20.3778"},{"doi-asserted-by":"publisher","key":"e_1_2_10_16_1","DOI":"10.1016\/j.leukres.2019.106188"},{"doi-asserted-by":"publisher","key":"e_1_2_10_17_1","DOI":"10.1182\/blood\u20102017\u201010\u2010811224"},{"doi-asserted-by":"publisher","key":"e_1_2_10_18_1","DOI":"10.1038\/bmt.2013.226"},{"issue":"2","key":"e_1_2_10_19_1","first-page":"1","article-title":"Managing risk in Hodgkin lymphoma","volume":"13","author":"Armitage JO","year":"2015","journal-title":"Clin Adv Hematol Oncol"},{"doi-asserted-by":"publisher","key":"e_1_2_10_20_1","DOI":"10.1182\/blood.V85.1.1.bloodjournal8511"},{"doi-asserted-by":"publisher","key":"e_1_2_10_21_1","DOI":"10.2165\/11591070\u2010000000000\u201000000"},{"doi-asserted-by":"publisher","key":"e_1_2_10_22_1","DOI":"10.1056\/NEJMoa1002965"},{"unstructured":"Seagen Inc.A Pivotal Study of SGN\u201035 in Treatment of Patients With Relapsed or Refractory Hodgkin Lymphoma (HL).clinicaltrials.gov;2017. Accessed July 29 2021.https:\/\/clinicaltrials.gov\/ct2\/show\/NCT00848926","key":"e_1_2_10_23_1"},{"doi-asserted-by":"publisher","key":"e_1_2_10_24_1","DOI":"10.1200\/JCO.2011.38.0410"},{"doi-asserted-by":"publisher","key":"e_1_2_10_25_1","DOI":"10.1182\/blood\u20102014\u201008\u2010595801"},{"doi-asserted-by":"publisher","key":"e_1_2_10_26_1","DOI":"10.1016\/S2352\u20103026(18)30153\u20104"},{"doi-asserted-by":"publisher","key":"e_1_2_10_27_1","DOI":"10.1182\/blood.V126.23.3982.3982"},{"doi-asserted-by":"publisher","key":"e_1_2_10_28_1","DOI":"10.1182\/blood.2020009178"},{"doi-asserted-by":"publisher","key":"e_1_2_10_29_1","DOI":"10.1182\/blood\u20102017\u201011\u2010815183"},{"doi-asserted-by":"publisher","key":"e_1_2_10_30_1","DOI":"10.1111\/bjh.16499"},{"doi-asserted-by":"publisher","key":"e_1_2_10_31_1","DOI":"10.1007\/s11912\u2010012\u20100251\u2010y"},{"doi-asserted-by":"publisher","key":"e_1_2_10_32_1","DOI":"10.1200\/JCO.2012.45.3308"},{"doi-asserted-by":"publisher","key":"e_1_2_10_33_1","DOI":"10.1016\/j.clml.2015.02.023"},{"doi-asserted-by":"publisher","key":"e_1_2_10_34_1","DOI":"10.1111\/bjh.12548"},{"doi-asserted-by":"publisher","key":"e_1_2_10_35_1","DOI":"10.1182\/blood.V126.23.2479.2479"},{"doi-asserted-by":"publisher","key":"e_1_2_10_36_1","DOI":"10.1182\/blood.V126.23.586.586"},{"doi-asserted-by":"publisher","key":"e_1_2_10_37_1","DOI":"10.2217\/fon\u20102016\u20100160"},{"doi-asserted-by":"publisher","key":"e_1_2_10_38_1","DOI":"10.1111\/bjh.17274"},{"doi-asserted-by":"publisher","key":"e_1_2_10_39_1","DOI":"10.1182\/bloodadvances.2021005268"},{"doi-asserted-by":"publisher","key":"e_1_2_10_40_1","DOI":"10.1182\/blood.V130.Suppl_1.4090.4090"},{"doi-asserted-by":"publisher","key":"e_1_2_10_41_1","DOI":"10.1200\/JCO.2013.54.8800"},{"doi-asserted-by":"publisher","key":"e_1_2_10_42_1","DOI":"10.1200\/JCO.2016.67.7104"},{"doi-asserted-by":"publisher","key":"e_1_2_10_43_1","DOI":"10.1097\/HS9.0000000000000329"},{"doi-asserted-by":"publisher","key":"e_1_2_10_44_1","DOI":"10.1097\/00043426\u2010200101000\u201000008"},{"doi-asserted-by":"publisher","key":"e_1_2_10_45_1","DOI":"10.1080\/10428194.2020.1817434"},{"unstructured":"Bristol\u2010Myers Squibb.Risk\u2010Based Response\u2010Adapted Phase II Open\u2010Label Trial of Nivolumab + Brentuximab Vedotin (N + Bv) for Children Adolescents and Young Adults With Relapsed\/Refractory (R\/R) CD30 + Classic Hodgkin Lymphoma (CHL) After Failure of First\u2010Line Therapy Followed by Brentuximab + Bendamustine (Bv + B) for Participants With a Suboptimal Response (CheckMate 744: CHECKpoint Pathway and Nivolumab Clinical Trial Evaluation).clinicaltrials.gov;2020. Accessed November 11 2021.https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02927769","key":"e_1_2_10_46_1"},{"unstructured":"Columbia University.A Phase I\/II Clinical Trial of the Combination of Brentuximab Vedotin and Bendamustine in Patients With Relapsed or Refractory Hodgkin Lymphoma or Anaplastic Large Cell Lymphoma.clinicaltrials.gov;2020. Accessed July 29 2021.https:\/\/clinicaltrials.gov\/ct2\/show\/NCT01657331","key":"e_1_2_10_47_1"},{"doi-asserted-by":"publisher","key":"e_1_2_10_48_1","DOI":"10.1016\/S1470\u20102045(17)30912\u20109"},{"doi-asserted-by":"publisher","key":"e_1_2_10_49_1","DOI":"10.1111\/ejh.13400"},{"doi-asserted-by":"publisher","key":"e_1_2_10_50_1","DOI":"10.1182\/blood.V124.21.293.293"},{"doi-asserted-by":"publisher","key":"e_1_2_10_51_1","DOI":"10.1016\/S0140\u20106736(15)60165\u20109"},{"unstructured":"Fondazione Italiana Linfomi ONLUS.A Phase II Study With Bendamustine Plus Brentuximab Vedotin in Hodgkin's Lymphoma and CD30+ Peripheral T\u2010Cell Lymphoma in First Salvage Setting: The BBV Regimen.clinicaltrials.gov;2021. Accessed July 29 2021.https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02499627","key":"e_1_2_10_52_1"},{"doi-asserted-by":"publisher","key":"e_1_2_10_53_1","DOI":"10.1007\/s00277\u2010020\u201004204\u20101"},{"doi-asserted-by":"publisher","key":"e_1_2_10_54_1","DOI":"10.1200\/JCO.2015.63.0699"},{"doi-asserted-by":"publisher","key":"e_1_2_10_55_1","DOI":"10.1016\/j.ctrv.2019.06.002"},{"unstructured":"Bristol\u2010Myers Squibb.Risk\u2010Based Response\u2010Adapted Phase II Open\u2010Label Trial of Nivolumab + Brentuximab Vedotin (N + Bv) for Children Adolescents and Young Adults With Relapsed\/Refractory (R\/R) CD30 + Classic Hodgkin Lymphoma (CHL) After Failure of First\u2010Line Therapy Followed by Brentuximab + Bendamustine (Bv + B) for Participants With a Suboptimal Response (CheckMate 744: CHECKpoint Pathway and Nivolumab Clinical Trial Evaluation).clinicaltrials.gov;2020. Accessed July 29 2021.https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02927769","key":"e_1_2_10_56_1"}],"container-title":["Pediatric Blood &amp; Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/pbc.29557","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/pbc.29557","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/pbc.29557","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,27]],"date-time":"2023-08-27T16:54:53Z","timestamp":1693155293000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/pbc.29557"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,2,2]]},"references-count":55,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2022,4]]}},"alternative-id":["10.1002\/pbc.29557"],"URL":"https:\/\/doi.org\/10.1002\/pbc.29557","archive":["Portico"],"relation":{},"ISSN":["1545-5009","1545-5017"],"issn-type":[{"type":"print","value":"1545-5009"},{"type":"electronic","value":"1545-5017"}],"subject":[],"published":{"date-parts":[[2022,2,2]]},"assertion":[{"value":"2021-10-01","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2021-12-18","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-02-02","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e29557"}}